Mammary Cell News Volume 10.36 | Sep 13 2018

TOP STORY

HIC1 Deletion Promotes Breast Cancer Progression by Activating Tumor Cell/Fibroblast Crosstalk

The chemokine CXCL14 secreted by HIC1-deleted breast cancer (BrCa) cells bound to its novel cognate receptor GPR85 on mammary fibroblasts in the microenvironment and was responsible for activating these fibroblasts via the ERK1/2, Akt, and neddylation pathways, whereas the activated fibroblasts promoted BrCa progression via the induction of the epithelial-mesenchymal transition by the CCL17/CCR4 axis. [J Clin Invest] Abstract | Full Article | Graphical Abstract

(Ranked by impact factor of the journal)

Unravelling Subclonal Heterogeneity and Aggressive Disease States in TNBC through Single-Cell RNA-Seq

Researchers showed that intercellular heterogeneity of gene expression programs within each tumor is variable and largely correlated with clonality of inferred genomic copy number changes, suggesting that genotype drives the gene expression phenotype of individual subpopulations. [Nat Commun] Full Article

Phosphodiesterase 7B/MicroRNA-200c Relationship Regulates Triple-Negative Breast Cancer Cell Growth

Scientists identified phosphodiesterase 7B (PDE7B) as a bona fide miR-200c target. miR-200c-led inhibition in cell growth and tumor development was prevented by forcing PDE7B transgene expression, while knockdown of PDE7B effectively inhibited cell growth. [Oncogene] Abstract

Role of SUMOylation in Differential ERα Transcriptional Repression by Tamoxifen and Fulvestrant in Breast Cancer Cells

Decreasing SUMOylation by overexpressing the deSUMOylase SENP1 significantly delayed receptor release from DNA and de-repressed expression of estrogen target genes in the presence of fulvestrant, both in estrogen receptor alpha (ERα)-expressing MCF-7 cells and in transiently transfected ER-negative SK-BR-3 cells. [Oncogene] Full Article

Ligand-Activated Interaction of PPARδ with C-Myc Governs the Tumorigenicity of Breast Cancer

The authors showed that ligand-activated peroxisome proliferator-activated receptor δ (PPARδ) formed a complex with the proto-oncogene product c-Myc. The interaction of PPARδ with c-Myc affected the transcriptional activity of c-Myc and the expression of its target genes. The PPARδ-dependent regulation of c-Myc activity was associated with decreased tumorigenicity in breast cancer cells. [Int J Cancer] Abstract

Aberrant Expression of SETD1A Promotes Survival and Migration of Estrogen Receptor α-Positive Breast Cancer Cells

In addition to estrogen receptor α target genes, other cell survival genes were also downregulated by SETD1A depletion in MCF-7 cells, leading to significant decrease in cell proliferation and migration, and spontaneous induction of apoptosis. Scientists also found that miR-1915-3p functioned as a novel regulator of SETD1A expression in breast cells. [Int J Cancer] Abstract

KLLN-Mediated DNA Damage-Induced Apoptosis Is Associated with Regulation of p53 Phosphorylation and Acetylation in Breast Cancer Cells

KLLN expression was upregulated after doxorubicin-induced DNA damage and this upregulation could be abrogated using RNAi-mediated gene silencing. Silencing KLLN after doxorubicin treatment affected DNA damage response shown by decreased γ-H2AX foci and expression, and apoptosis assessed by decreased frequency of apoptotic nuclei and decreased expression of definitive markers of apoptosis. [Cell Death Discov] Full Article

Identification of Protein Kinase Inhibitors to Reprogram Breast Cancer Cells

Investigators developed a reprogramming method that used a conceptually unique strategy for breast cancer cell treatment. They found that Rho-associated protein kinase and mammalian target of rapamycin kinase inhibitors could substitute for all transcription factors to be sufficient to reprogram breast cancer cells into progenitor cells. [Cell Death Dis] Full Article

HDAC6 Inhibitor TST Strengthens the Antiproliferative Effects of PI3K/mTOR Inhibitor BEZ235 in Breast Cancer Cells via Suppressing RTK Activation

The adding of tubastatin A (TST) destabilized receptor tyrosine kinases (RTKs) in breast cancer cells. Co-treatment with NVP-BEZ235 (BEZ235) and TST reduced cell proliferative rate by strengthening Akt inactivation. The combination of these two drugs also cooperatively arrested cell cycle and DNA synthesis. [Cell Death Dis] Full Article

FGF18 Enhances Migration and the Epithelial-Mesenchymal Transition in Breast Cancer by Regulating Akt/GSK3β/Β-Catenin Signaling

Fibroblast growth factor 18 (FGF18) promoted the epithelial-mesenchymal transition and migration in breast cancer cells through activation of the Akt/GSK3β/β-catenin pathway. FGF18 increased Akt-Ser473 and -Thr308 phosphorylation, as well as that of GSK3β-Ser9. [Cell Physiol Biochem] Full Article

TTK Promotes Mesenchymal Signaling via Multiple Mechanisms in Triple Negative Breast Cancer

Scientists found that higher TTK expression correlated with mesenchymal and proliferative phenotypes in triple negative breast cancer (TNBC) cells. Pharmacologic inhibition and genomic silencing of TTK not only reversed the epithelial-to-mesenchymal transition (EMT) in TNBC cells, but also increased the expression of KLF5, an effector of TGF-β signaling and inhibitor of EMT. [Oncogenesis] Full Article

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Progress in Adjuvant Systemic Therapy for Breast Cancer

The authors summarize attempts to escalate and de-escalate adjuvant systemic treatment for patients with breast cancer and argue that new, creative trial designs focused on patients’ actual needs rather than on maximizing drug market size are needed. [Nat Rev Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

BioIVT Launches Dissociated Tumor Cell (DTC) Product Line to Advance Oncology Research

BioIVT announced the addition of a DTC product line to its immunology portfolio. Researchers can use patient-derived DTCs to determine how specific cohorts of cancer cells will react to different drug therapies. [BioreclamationIVT.] Press Release

1st Patient Dosed in Phase Ib Clinical Trial of Cirmtuzumab in Combo w/ Paclitaxel in Patientss w/ Breast Cancer

Oncternal Therapeutics, Inc. announced the first patient has been dosed in a Phase Ib study of cirmtuzumab, an anti-ROR1 monoclonal antibody, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advanced, unresectable breast cancer. [Oncternal Therapeutics] Press Release

Quantum Leap Healthcare Collaborative Announces AstraZeneca’s Olaparib and Durvalumab‎ for the I-SPY 2 Trial for Breast Cancer

Quantum Leap Healthcare Collaborative^™ announced that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL^™ includes the study of olaparib and durvalumab, two agents from AstraZeneca. [Quantum Leap Healthcare Collaborative] Press Release

HHMI Awards Hanna Gray Fellowships to 15 Early Career Scientists

The Howard Hughes Medical Institute (HHMI) announced the selection of 15 outstanding early career scientists as HHMI Hanna Gray Fellows. These recent PhD and MD/PhD recipients will continue their training as postdoctoral fellows at 12 institutions in the U.S. [Howard Hughes Medical Institute] Press Release

Prominent Health Policy Researcher Resigns from Dartmouth Over Plagiarism Dispute

Dr. H. Gilbert Welch, one of the country’s top health care policy scholars, has resigned from his faculty position at Dartmouth College, after an investigation by the school concluded that he had committed research misconduct. [STAT News] Editorial

Peer Reviewers Unmasked: Largest Global Survey Reveals Trends

Scientists in developed countries provide nearly three times as many peer reviews per paper submitted as researchers in emerging nations, according to the largest ever survey of the practice. [Nature News] Editorial

Europe’s Academics Fail to Report Results for 90% of Clinical Trials

European academics are failing abysmally when it comes to reporting the results of clinical trials, a study has revealed. An analysis of data from the European Union’s Clinical Trial Register — published in The BMJ — shows that around 50% of the listed trials have not complied with guidelines that say results must be reported within 12 months. [Nature News] Editorial

NEW AACR: The Hippo Pathway: Signaling, Cancer, and Beyond
May 8-11, 2019
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Immunotherapy of Breast Cancer (Boston University School of Medicine)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine)

Postdoctoral Position – Cancer Biology (GIGA – Universite de Liege)

Research Assistant II – Breast Medical Oncology (MD Anderson Cancer Center)

Cancer Faculty Investigators – Breast Cancer (The University of Alabama)

Tenure-Track Assistant Professor – Breast Cancer Biology (Johns Hopkins University School of Medicine)

Postdoctoral Fellow/Research Scientist – Cancer Research (Icahn School of Medicine at Mount Sinai)

Postdoctoral Positions – Breast Cancer Research (UPMC Hillman Cancer Center)

Cancer Faculty Investigators – Cancer Research (University of Alabama at Birmingham)

Postdoctoral Research Fellow – Immuno/Oncology of Breast Cancer (Henry M. Jackson Foundation)

Postdoctoral Position – Breast Cancer (University of Trento)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.